RBC Sees Long-Term and Near-Term Upside for Regeneron (REGN); PT to $550
Tweet Send to a Friend
RBC Capital analyst Adnan Butt reiterated an Outperform rating and bumped his price target on Regeneron Pharma (NASDAQ: REGN) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE